[Short Educational Video] CMIC Group Released Two C-CASTs on;
- Expedited Review Programs in Japan
- In-Country Clinical Caretaker (ICCC) for Clinical Trials in Japan
OrphanPacific Inc. measures to continue to serve the community while respecting the instructions from the government of the COVID-19
Response and Support During COVID-19 Pandemic
(Will be linked to CMIC Group website)
[Webinar Archive Available] Orphan drug development in Japan - How can we accelerate rare disease patients’ access to therapies? -
OrphanPacific Inc. measures to contain the further spread of the new corona-virus
Learn More about Japanese Market Entry
Announcement of Marketing Authorization Transfer and Product Name Change of DIAZOXIDE Capsules 25 mg "MSD"
OrphanPacific, Inc. Exhibited and Presented at World Orphan Drug Congress USA 2019
OrphanPacific, Inc. to Present at World Orphan Drug Congress USA 2019
OrphanPacific/CMIC Group sponsors “Rare Disease Day 2019” in Japan.
OrphanPacific have Co-hosted the Rare Disease Activity at the "Hamamatsucho building Social Contribution Day 2018"
[Webinar Recording Available]
Tips to Ensure Market Entry Success in Japan
Challenges, Regulatory Updates and Success Factors
Started sales of Rasilez in Japan
Updated the Product List page and Company History
Top Management Message
We support Rare Disease Day 2018 in Japan
Took over the manufacturing and sales of Rasilez® Tablets 150mg in Japan
CMIC Group sponsors Rare Disease Day 2018 in Japan.
[CMIC Group Page will open]
Announcement of manufacturing and sales transfer of Rasilez® Tablets 150mg
Announcement of business alliance (MR activities /medical information support)
Termination of the collaboration to launch Flu Virus Kit MINUTEREAD®Flu ( PDF/ 239KB )
Announcement of sales transfer of DIAZOXIDE Capsules25 mg "MSD" (PDF/ 266KB)